Status:
COMPLETED
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
Lead Sponsor:
Ipsen
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms o...
Detailed Description
The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed ...
Eligibility Criteria
Inclusion
- Age ≥18 years old
- Has a diagnosis of advanced RCC
- Has received at least one prior VEGF-targeted therapy
- For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion
- No previous exposure to cabozantinib prior to inclusion
- Not concurrently involved in an interventional study
- Consents to participate in this noninterventional study
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
April 24 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 19 2022
Estimated Enrollment :
689 Patients enrolled
Trial Details
Trial ID
NCT03419572
Start Date
April 24 2018
End Date
May 19 2022
Last Update
August 15 2022
Active Locations (91)
Enter a location and click search to find clinical trials sorted by distance.
1
Kepler University Hospital - Urology
Linz, Austria, 4020
2
Universitatsklinikum fur Urologie und Andrologie
Salzburg, Austria, 5020
3
Imelda Ziekenhuis
Bonheiden, Belgium, 2820
4
Az Klina
Brasschaat, Belgium, 2930